Johnson & Johnson currently exhibits a stronger overall position by generating a substantially larger total revenue volume than Novo Nordisk.
Johnson & Johnson maintained a consistent quarter-over-quarter upward trajectory, while Novo Nordisk reported mostly flat U.S. dollar figures with the exception of one isolated spike.
Investors should watch whether this distinct revenue gap continues to widen or if the two companies begin to show converging trend lines in upcoming quarters.
Johnson & Johnson (NYSE:JNJ) primarily generates revenue by developing and selling pharmaceutical treatments and medical technology products worldwide.
It recently secured two regulatory approvals for new medical treatments, and it launched a cardiovascular catheter device in the United States.
Novo Nordisk (NYSE:NVO) earns its revenue by developing and producing specialized pharmaceutical therapies for diabetes, obesity care, and rare blood disorders.
It received European marketing authorization for a hemophilia treatment, while facing a new regulatory requirement to add warning labels to certain existing medications.
Revenue here refers to the data provider's standardized income-statement revenue line item, which serves as a baseline indicator of total sales volume and overall market demand.
Johnson & Johnson vs. Novo Nordisk Revenue over the last 8 quarters. Figures: Novo Nordisk shown in U.S. dollars, converted from Danish kroner.
| Calendar quarter | Johnson & Johnson Revenue | Novo Nordisk Revenue |
|---|---|---|
| Q4 2024 | $22.5 billion (quarter ended Dec. 29, 2024) | $12.2 billion (quarter ended Dec. 31, 2024) |
| Q1 2025 | $21.9 billion (quarter ended March 30, 2025) | $11.0 billion (quarter ended March 31, 2025) |
| Q2 2025 | $23.7 billion (quarter ended June 29, 2025) | $11.7 billion (quarter ended June 30, 2025) |
| Q3 2025 | $24.0 billion (quarter ended Sept. 28, 2025) | $11.7 billion (quarter ended Sept. 30, 2025) |
| Q4 2025 | $24.6 billion (quarter ended Dec. 28, 2025) | $12.3 billion (quarter ended Dec. 31, 2025) |
| Q1 2026 | $24.1 billion (quarter ended March 29, 2026) | $15.1 billion (quarter ended March 31, 2026) |
| Q2 2026 | $25.3 billion (quarter ended June 28, 2026) | $12.2 billion (quarter ended June 30, 2026) |
| Q3 2026 | $25.4 billion (quarter ended Sept. 27, 2026) | $12.2 billion (quarter ended Sept. 30, 2026) |
The first thing to check for when examining a company's revenue trend is seasonality: some times of the year have stronger buying patterns than others. There usually is some seasonality for every business.
There can be seasonality in healthcare stocks, often seen as consumers spend more in the fourth calendar quarter to take advantage of insurance deductibles being met. We see some seasonality in Johnson & Johnson's business from that, with Q1 revenue ticking down compared to prior quarters. In such cases, compare year-over-year results, so Q1 2026 compared to Q1 2025 shows a rise in revenue.
Even wth that seasonality, JNJ shows positive revenue growth overall in the chart, and no wonder--the business has 28 products and platforms that generate more than $1 billion in annual revenue.
Given the nature of its primary product, GLP-1s, which need to be taken continuously, Novo Nordisk doesn't see a lot of seasonality in its business. Yet the chart shows that the company is struggling to find sales momentum as competitors catch up with their weight loss offerings.
Revenue trend is the most obvious figure for investors to examine when considering a stock. The chart shows that one business is thriving while the other is seeking to regain its footing.
Data source: Financial Modeling Prep. Novo Nordisk's figures are converted from Danish kroner to U.S. dollars. Data as of Nov. 16, 2026.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Novo Nordisk. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.